文献速递妇科

新辅助化疗时代卵巢癌手术复杂性与治疗模式的趋势

Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
PubMed 文献 · Gynecol Oncol · 2019-06-11

基于美国国家癌症数据库的回顾性队列研究,纳入2004至2015年诊断为III或IV期上皮性卵巢癌的妇女,比较初次肿瘤细胞减灭术后辅助化疗与新辅助化疗后间歇性肿瘤减灭术。新辅助化疗使用率从2004年7.7%升至2015年27.8%(趋势P<0.001),中等及高复杂度手术比例均上升,30天死亡率从3.4%降至1.4%,90天死亡率从7.6%降至4%,5年生存率从39.7%升至49%。

要点

  • 新辅助化疗使用率从2004年7.7%升至2015年27.8%(趋势P<0.001)。
  • 中等复杂度手术从28.9%升至33.5%,高复杂度手术从26.3%升至30%(趋势P均<0.001)。
  • 30天死亡率从3.4%降至1.4%,90天死亡率从7.6%降至4%,5年生存率从39.7%升至49%。

核心结论

  • 新辅助化疗使用增加与30天和90天死亡率降低及5年生存率升高相关。
  • 在初次肿瘤细胞减灭术和新辅助化疗两个队列中,卵巢癌手术的总体复杂度均增加。

研究设计与样本

  • 利用美国国家癌症数据库开展的回顾性队列研究,纳入2004至2015年诊断为III或IV期上皮性卵巢癌并接受初次肿瘤细胞减灭术后辅助化疗或新辅助化疗后间歇性肿瘤减灭术的妇女。
  • 共52,582例(76.3%)接受初次肿瘤细胞减灭术,16,307例(23.7%)接受新辅助化疗。
  • 手术复杂度分为不足、低、中等和高复杂度四类,主要结局为手术复杂度随时间的变化趋势。

主要发现

  • 新辅助化疗使用率从2004年7.7%升至2015年27.8%(趋势P<0.001)。
  • 中等复杂度手术从28.9%升至33.5%,高复杂度手术从26.3%升至30%(趋势P均<0.001)。
  • 手术复杂度增加趋势在新辅助化疗和初次肿瘤细胞减灭术两个队列中均可见,且在高容量中心最为明显。
  • 30天死亡率从2004年3.4%降至2015年1.4%,90天死亡率从7.6%降至4%,5年生存率从39.7%升至49%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the impact of the increased use of neoadjuvant chemotherapy on the complexity of cytoreductive surgeries for ovarian cancer. METHODS: Using the National Cancer Database, we performed a retrospective cohort study of women diagnosed between 2004 and 2015 with stage III or IV epithelial ovarian cancer who underwent either primary cytoreductive surgery (PDS) followed by adjuvant chemotherapy, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery. Cases were assigned a surgical complexity category as 1) Inadequate, 2) Low, 3) Moderate and, 4) High complexity. The primary outcome was the trend in surgical complexity over time. Secondary outcomes included temporal trends in treatment modality, perioperative mortality, and survival. RESULTS: At total of 52,582 (76.3%) underwent PDS and 16,307 (23.7%) underwent NACT. The utilization of NACT increased from 7.7% in 2004 to 27.8% in 2015 (p-trend < 0.001). Patients undergoing moderate complexity surgeries increased from 28.9% to 33.5% and high complexity surgeries from 26.3% to 30% (p-trend < 0.001, for both). Trends in increasing surgical complexity were seen in both NACT and PDS cohorts. This increase in surgical complexity was seen most profoundly at the high-volume centers. Overall 30-day mortality decreased from 3.4% in 2004 to 1.4% in 2015; and 90-day mortality decreased from 7.6% to 4%. During the same time, 5-year survival increased from 39.7% to 49%. CONCLUSIONS: Increase in the utilization of NACT is associated with decreased 30- and 90-day mortality and increase in five-year survival. Moreover, the overall complexity of ovarian cancer surgery has increased in both PDS and NACT cohorts.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Horner W, Peng K, Pleasant V, et al. Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy. Gynecol Oncol. 2019. PMID: 31196575. doi:10.1016/j.ygyno.2019.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。